Hannah Ryles to Pyrazoles
This is a "connection" page, showing publications Hannah Ryles has written about Pyrazoles.
Connection Strength
0.163
-
ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma. Cancer Cell. 2014 Nov 10; 26(5):682-94.
Score: 0.106
-
The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma. Cancer Discov. 2016 Jan; 6(1):96-107.
Score: 0.028
-
Crizotinib Synergizes with Chemotherapy in Preclinical Models of Neuroblastoma. Clin Cancer Res. 2016 Feb 15; 22(4):948-60.
Score: 0.028